United Therapeutics (NASDAQ:UTHR) Price Target Raised to $350.00

United Therapeutics (NASDAQ:UTHR) had its target price lifted by Wells Fargo & Company from $325.00 to $350.00 in a research report sent to investors on Wednesday morning, Benzinga reports. Wells Fargo & Company currently has an overweight rating on the biotechnology company’s stock.

A number of other research analysts have also recently commented on the company. HC Wainwright reaffirmed a buy rating and set a $300.00 price target on shares of United Therapeutics in a research report on Thursday, May 2nd. Wedbush reiterated an outperform rating and set a $308.00 target price on shares of United Therapeutics in a research report on Thursday, February 22nd. StockNews.com upgraded shares of United Therapeutics from a buy rating to a strong-buy rating in a research note on Wednesday. Oppenheimer upped their price target on shares of United Therapeutics from $375.00 to $400.00 and gave the company an outperform rating in a research note on Thursday, May 2nd. Finally, The Goldman Sachs Group lifted their price objective on shares of United Therapeutics from $218.00 to $240.00 and gave the company a neutral rating in a research note on Friday, May 3rd. One analyst has rated the stock with a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, United Therapeutics currently has a consensus rating of Buy and a consensus target price of $312.22.

United Therapeutics Price Performance

UTHR opened at $288.06 on Wednesday. United Therapeutics has a fifty-two week low of $208.62 and a fifty-two week high of $288.83. The firm has a 50-day moving average of $259.42 and a 200 day moving average of $238.99. The company has a debt-to-equity ratio of 0.04, a quick ratio of 3.64 and a current ratio of 3.77. The firm has a market cap of $12.78 billion, a P/E ratio of 13.62, a PEG ratio of 4.28 and a beta of 0.49.

United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, May 1st. The biotechnology company reported $6.17 earnings per share for the quarter, beating analysts’ consensus estimates of $5.63 by $0.54. United Therapeutics had a net margin of 42.05% and a return on equity of 18.72%. The firm had revenue of $677.70 million during the quarter, compared to the consensus estimate of $620.31 million. During the same period in the prior year, the firm earned $4.86 EPS. The company’s revenue was up 33.7% compared to the same quarter last year. On average, research analysts expect that United Therapeutics will post 24.61 EPS for the current year.

Insider Transactions at United Therapeutics

In related news, Director Christopher Causey sold 2,000 shares of United Therapeutics stock in a transaction on Thursday, June 13th. The stock was sold at an average price of $281.53, for a total transaction of $563,060.00. Following the completion of the sale, the director now owns 4,185 shares of the company’s stock, valued at $1,178,203.05. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In other United Therapeutics news, Director Christopher Causey sold 2,000 shares of the firm’s stock in a transaction dated Thursday, June 13th. The stock was sold at an average price of $281.53, for a total value of $563,060.00. Following the sale, the director now owns 4,185 shares of the company’s stock, valued at approximately $1,178,203.05. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Nilda Mesa sold 325 shares of United Therapeutics stock in a transaction dated Wednesday, March 27th. The shares were sold at an average price of $237.80, for a total value of $77,285.00. Following the sale, the director now owns 5,373 shares of the company’s stock, valued at approximately $1,277,699.40. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 177,128 shares of company stock valued at $43,561,905. 12.50% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On United Therapeutics

A number of institutional investors have recently made changes to their positions in the stock. Jump Financial LLC bought a new position in United Therapeutics in the third quarter valued at $251,000. J.P. Morgan Private Wealth Advisors LLC raised its holdings in shares of United Therapeutics by 6.1% during the 3rd quarter. J.P. Morgan Private Wealth Advisors LLC now owns 1,275 shares of the biotechnology company’s stock valued at $288,000 after buying an additional 73 shares in the last quarter. Janney Montgomery Scott LLC lifted its position in United Therapeutics by 17.0% in the 3rd quarter. Janney Montgomery Scott LLC now owns 8,809 shares of the biotechnology company’s stock worth $1,990,000 after buying an additional 1,279 shares during the last quarter. Van ECK Associates Corp boosted its stake in United Therapeutics by 0.9% in the third quarter. Van ECK Associates Corp now owns 9,685 shares of the biotechnology company’s stock worth $2,188,000 after buying an additional 84 shares in the last quarter. Finally, Pathstone Family Office LLC purchased a new stake in United Therapeutics in the third quarter worth approximately $369,000. Institutional investors own 94.08% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.